| dc.description.abstract |
Objectives: To determine the prevalence, clinical characteristics and outcomes of HIV and severe acute respiratory syndrome coronavirus 2 (SARS−CoV−2) co−infection.; Methods: We searched Medline, Embase, Cochrane and Web of Science databases and grey literature for studies reporting epidemiological and clinical data of patients with HIV and SARS−CoV−2 co−infection. Eligible studies were all observational or interventional studies and commentaries in English language that reported patient data on HIV/SARS−CoV−2 co−infection. We used random effect meta−analysis to determine the pooled prevalence and mortality.; Results: Of the 17 eligible studies, there were 3 retrospective cohorts, 1 survey, 5 case series, 7 case reports and 1 commentary that reported on a total of 146 HIV infected individuals. The pooled prevalence of HIV among individuals with SARS−CoV−2 infection was 1.0% (95% CI: 0.0 − 3.0, I2 = 79.3%, p=0.01), whereas the prevalence of SARS−CoV−2 among HIV patients was 0.68% (95% CI: 0.34 − 1.34). There were 110 (83.8%) HIV/ SARS−CoV−2 co−infected males, and the age (range) of the co−infected was 30 − 60 years. A total of 129 (97.0%) were anti−retroviral therapy experienced, and 113 (85.6%) had a suppressed HIV viral load. The CD4 count (range) was 298 − 670 cells/mm3 (n = 107). The commonest symptoms were fever (73.5%, n=75) and cough (57.8%, n = 59). Sixty−two (65.3%) patients had at least one other comorbid condition, of which hypertension (26.4%, n = 38) was the commonest. Chest radiological imaging abnormalities were found in 46 (54.1%) cases. Twenty-eight cases (56.0%) were reported as mild. Recovery occurred in 120 (88.9%) cases, and the pooled mortality was 9% (95% CI: 3.0 − 15.0, I2 = 25.6%, p =0.24).; Conclusion: The prevalence of HIV/SARS−CoV−2 co−infection was low. The clinical characteristics and outcomes of HIV/SARS−CoV−2 co−infection are comparable to those reported among HIV negative SARS−CoV−2 cases. |
|